Posted by Michael Wonder on 30 Dec 2022
Heron Therapeutics announces filing of an efficacy supplement for Zynrelef and provision in newly passed congressional bill anticipated to provide separate reimbursement outside of the packaged surgical payment for Zynrelef
29 December 2022 - Supplemental new drug application submitted requesting expansion of indication to broadly cover soft tissue and orthopaedic surgical procedures.
Heron Therapeutics today announced the submission of a supplemental new drug application for Zynrelef (bupivacaine and meloxicam) extended-release solution to support the proposed indication for greatly expanded use of Zynrelef in soft tissue and orthopaedic surgical procedures.
